Development pipeline
| Development code; Target/Indication(s) |
Target exploration | Optimization (sequence, type of nucleic acid) |
Efficacy, toxicity, metabolism studies, etc. (Preliminary nonclinical studies) |
Non-clinical studies | Phase I | Phase II |
|---|---|---|---|---|---|---|
| BNC-1021/TRK-250; TGF-β1/IPF |
 |
|
|
|
|
- |
| BNC-1601; (pro)renin receptor/AMD, Uveitis, Diabetic retinopathy |
|
|
|
- | - | - |
| BNC-1701; Virus/HBV |
|
|
|
- | - | - |
| BNC-1322； SARS-CoV-2/COVID-19 |
|
|
|
- | - | - |
| BNC-1602; miR29b/liver fibrosis |
|
|
|
- | - | - |
| Not disclosed | |
|
- | - | - | - |
